Category: Therapeutic Area
Global Therapeutic Area
-
Bone and Joint Health Supplements
... is expected to reach US$22.0 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Joint Supplements, one of the segments analyzed in the report, is expected to record a 6.3% ... Read More
-
Testosterone Replacement Therapy (TRT)
... reach US$2.5 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. TRT Topicals, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% ... Read More
-
Peptic Ulcer Testing
... by 2030, growing at a CAGR of 5.5% over the analysis period 2023-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$410.6 Million by ... Read More
-
Infection Surveillance Solutions
... by 2030, growing at a CAGR of 14.2% over the period 2023-2030. Infection Surveillance Software, one of the segments analyzed in the report, is expected to record 13.7% CAGR and reach US$1.2 Billion by the ... Read More
-
Breast Biopsy Devices
... by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$983.4 Million ... Read More
-
Melanoma Therapeutics
... at a CAGR of 13.8% over the analysis period 2023-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$4.3 Billion by the end ... Read More
-
Pediatric Drugs and Vaccines
... reach US$156.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach ... Read More
-
Cardiovascular Catheters
... at a CAGR of 6.5% over the analysis period 2023-2030. Cardiovascular Therapeutic Catheters, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$25.4 Billion by the end ... Read More
-
Gastrointestinal (GI) Endoscopy Devices
... reach US$49.9 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), one of the segments analyzed in the report, is expected to record a 5.3% ... Read More
-
Lymphoma Therapeutics
... at a CAGR of 6.6% over the analysis period 2023-2030. Non-Hodgkin Lymphoma (NHL) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$20.5 Billion by the ... Read More
-
Adult Stores
... at a CAGR of 6.8% over the analysis period 2023-2030. Sex Toys, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$34.6 Billion by the end of ... Read More
-
Prescription Drugs
... at a CAGR of 5.7% over the analysis period 2023-2030. Generics, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$498.0 Billion by the end of the ... Read More
-
Global Age-Related Macular Degeneration Market Forecast Report by Disease Type (Dry Age-Related Macular Degeneration Market, Wet Age-Related Macular Degeneration Market) Product (Eylea, Lucentis, Beovu, Others) Distribution Channel (Hospital Pharmacy, Specialty Pharma, Online Pharmacy) Countries and Company Analysis, 2024-2032
... Company Analysis, 2024-2032 Age-Related Macular Degeneration Market Analysis The Global Age-Related Macular Degeneration market is forecasted to reach US$ 19.53 billion by 2032 from US$ 10.68 billion in 2023, and compound annual growth rate of ... Read More
-
Orthopedic Veterinary Implants
... by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Veterinary Bone Plates, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$86.4 Million ... Read More
-
Cancer Therapies
... at a CAGR of 10.4% over the analysis period 2023-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$112.8 Billion by the end of the ... Read More
-
Carotid Stents
... at a CAGR of 8.7% over the analysis period 2023-2030. Balloon Expandable Stents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$4.3 Billion by the end ... Read More
-
Antibiotics
... of 3.1% over the analysis period 2023-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth ... Read More
-
Brachytherapy
... of 4.4% over the analysis period 2023-2030. High Dose Rate Brachytherapy, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Human Growth Hormone Drugs
... reach US$5.2 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach ... Read More
-
Dental Infection Control Products
... reach US$2.3 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Dental Infection Control Consumables, one of the segments analyzed in the report, is expected to record a 7.7% CAGR ... Read More
-
Lung Cancer Diagnostics
... by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.3 Billion by ... Read More
-
CNS Therapeutics
... at a CAGR of 7.2% over the analysis period 2023-2030. Neurodegenerative Diseases Therapeutics, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$75.9 Billion by the end ... Read More
-
Colorectal Cancer Therapeutics
... by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by ... Read More
-
Bladder Cancer Therapeutics
... by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Transitional Cell Bladder Cancer Therapeutics, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach ... Read More
Research Assistance
